{"entity":{"id":"nct05557838","kind":"trial","name":"Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC","aka":[],"tldr":"A phase 3 trial of Durvalumab, Tremelimumab in hepatocellular carcinoma, run by AstraZeneca, active and no longer recruiting.","summary":"Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC is a phase 3 interventional study registered as NCT05557838 by AstraZeneca, with 214 participants enrolled, started 2023-02-15 and due to reach its primary completion in 2026-09-30. Interventions recorded: Durvalumab, Tremelimumab. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05557838","url":"https://clinicaltrials.gov/study/NCT05557838"}],"tags":["ctgov-ingest"],"related":[],"cancers":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":["durvalumab","tremelimumab"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05557838","phase":"3","setting":"An Open-label, Multi-center Phase IIIb Study of Durvalumab and Tremelimumab as First-Line Treatment in Patients With Unresectable Hepatocellular Carcinoma","sponsor":"AstraZeneca","enrolled":214,"outcomes":[]},"route":"/trials/nct05557838/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"drug":[{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"},{"id":"tremelimumab","kind":"drug","name":"Tremelimumab","route":"/drugs/tremelimumab/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}